智通财经APP获悉，全球罕见病公司Immedica Pharma将通过收购要约和随后合并收购Marinus Pharmaceuticals (MRNS.US)。此次收购补充并进一步加强了Immedica的全球罕见病业务。截至发稿，Marinus 股价周一盘前大涨43.78%。
Immedica将通过全资子公司发起收购要约，以每股0.55美元的现金收购Marinus的所有股份，按Marinus12月27日的收盘价计算，溢价为48%。该交易预计将于2025年第一季度完成。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.